Sangamo secures $50M upfront in neurodegenerative pact with Roche's Genentech

Biogen and Novartis may have walked away from partnerships with Sangamo Therapeutics last year, but that hasn't stopped Roche from seeking out a pact with the biotech to work on intravenous genomic medicines for neurodegenerative diseases.